The Scientist Pipeline Ends at the Grant

Executive Summary. Bangladesh has a science-grant programme, universities, laboratories, and researchers. What it lacks is a public conversion system that follows a grant into a verified result. WIPO's latest country profile records 116 patent applications by Bangladesh-resident applicants in 2024, the same count as in 2015 and below the 2016 peak of 149. Only 29 resident-origin applications were filed abroad. At the Bangladesh IP office, 302 of 389 applications came from non-residents, while the office issued 139 patent grants. These figures do not prove that a Ministry grant failed to produce a patent. Patents are only one output, and the sources cannot link grants to applications. That missing link is the policy problem. Bangladesh should assign each public research award a persistent identifier and publish its proposal, milestones, datasets, outputs, replication status, intellectual-property route, adoption, and follow-on finance. The grant should be the start of accountable research, not the last event the state can see.

A scientist who wins a public grant enters a system of approvals, procurement, reporting, and deadlines. The project may produce a dataset, method, paper, prototype, diagnostic, crop variety, process improvement, or negative result. Each output can have value. Yet the public usually sees the award announcement and little else in a form that can be followed across time.

This makes research policy strangely input-heavy. Ministries can show that money was allocated and projects were selected. Universities can show activity. Researchers can list publications. The country cannot easily answer which publicly funded results were independently verified, reused, patented where appropriate, adopted by an agency, licensed by a firm, or retired after evidence showed they did not work.

The output signal is flat, not absent

WIPO's country profile provides one visible system-level output. Applications by Bangladesh-resident applicants moved from 116 in 2015 to 149 in 2016, fell to 75 in 2017, recovered to 90 in 2019, dropped to 57 in 2020, and returned to 116 in 2024. The series fluctuates without establishing a sustained rise.

Source: WIPO, Intellectual property statistical country profile: Bangladesh, 2024.

This is not evidence that Bangladeshi science produced nothing. Many valuable results should not be patented. Public-health protocols, open datasets, policy methods, ecological monitoring, and basic research may create more value through open use. Some inventions are protected as know-how, design, copyright, or plant variety. Others are never commercialised for reasons unrelated to scientific quality.

The chart is still a useful warning. A country trying to build a research economy should be able to explain its output portfolio. If patents remain flat, perhaps open outputs expanded. If university-industry projects grew, perhaps licensing or adoption rose. If research targeted public services, perhaps procurement or programme results improved. Without a joined ledger, policymakers cannot test any of these alternatives. The absence of a patent surge is not the conclusion. The absence of a credible explanation is.

WIPO also reports 0.5 resident patent applications per million inhabitants. That intensity measure is a reminder that the national total is small relative to population. It should motivate investigation into barriers, not a quota that rewards weak applications.

Filing abroad is a demanding test of perceived value

Of the 116 applications attributed to Bangladesh-resident applicants in 2024, 87 were filed at home and 29 abroad. An abroad filing can be expensive and complex, so it is not a universal measure of quality. A locally useful invention may need only domestic protection. Yet an applicant's decision to bear foreign filing cost can signal an expectation of wider commercial value.

Source: WIPO, applications by Bangladesh-resident applicants, 2024.

The small abroad count points to several possible breaks. Researchers may not know when publication destroys novelty. Universities may lack technology-transfer support. Firms may not be engaged early enough to validate demand. Prototype funding may end before regulatory testing or scale-up. Foreign filing finance may be unavailable even when the case is strong.

These are hypotheses, not findings established by the WIPO profile. A research-output ledger would let Bangladesh test them. It could show how many projects disclosed an invention, received a prior-art search, chose open release, filed locally, sought foreign protection, formed a licensing plan, or stopped after a documented assessment. A stopped project is not necessarily a failure. An undocumented disappearance is.

The pipeline should also protect openness. Technology-transfer offices can become patent factories if judged by filings alone. The decision record should ask which route maximises public value: open publication, public-domain standard, data release, domestic protection, international protection, procurement, or further research. The point is not to patent everything. It is to make the route deliberate and reviewable.

The IP office shows demand, but not the grant-to-use chain

The Bangladesh IP office received 389 patent applications in 2024. Of these, 87 were resident and 302 non-resident. It issued 139 patent grants. The application population and the grant population are not necessarily the same cohort, so the two counts should not be divided to create a same-year approval rate.

Source: WIPO, Bangladesh IP office statistics, 2024. Applications and grants are counts, not a same-cohort conversion rate.

The non-resident majority shows that the domestic office is part of a wider market for rights. It does not show that domestic researchers are connecting successfully to domestic firms. A foreign applicant may protect a product intended for Bangladesh while a local university result never reaches an application, a licence, or a public buyer.

This is where the title's "pipeline" matters. The Ministry of Science and Technology grant page confirms an award mechanism. WIPO confirms downstream IP activity. The public sources do not provide a common identifier that connects the two. No responsible analysis can claim how many Ministry grants produced the applications or grants in the chart.

That causal limitation should shape reform. Bangladesh does not first need another aggregate target. It needs traceability. Each funded project should be linkable to outputs and decisions without forcing every project toward the same output. Once the links exist, evaluation can compare fields, grant types, institutions, and time horizons honestly.

Research fails when procurement treats evidence as a stranger

Even a strong prototype can stall if no institution owns the transition from research to use. A grant may finance proof of concept but not validation, certification, manufacturing design, field testing, or procurement. Universities may finish their contractual report while firms and agencies see an unready product. The gap is organisational, not merely financial.

Mission-oriented programmes can bridge it by naming a problem owner at the start. A health agency, agricultural extension service, utility, or local government should help define the operational need and evidence standard. Independent reviewers should test whether the result works outside the originating lab. Procurement rules should permit a transparent pilot without guaranteeing a later contract.

Negative results deserve a place in this system. If a method fails replication or a prototype cannot meet cost and safety requirements, publication prevents another team from repeating the same dead end. A grant ledger that records only success encourages quiet burial. A system that rewards usable knowledge records why a route stopped.

Skills and incentives must follow. Researchers need help with data management, reproducible methods, research contracts, prior art, regulation, and licensing. Promotion systems should recognise high-quality datasets, replications, standards, and adoption, not only paper counts. Firms need a clear route to discover projects without capturing the selection process.

The gender signal also deserves attention. WIPO reports women at 11.1% of inventors in its recent PCT-related window. That figure covers a narrow patent channel, not all scientists. It nevertheless asks whether research teams, ownership, mentorship, and commercialisation support distribute opportunity fairly.

The counterargument: patents are the wrong measure for public science

The strongest objection says this entire frame imports a commercial metric into research. Patents can reward secrecy, block diffusion, and overstate novelty. Bangladesh needs better teaching, basic science, public health, climate knowledge, and agricultural research, much of which should remain open.

The objection is correct about the metric and wrong about the proposed system. The case is not for patent maximisation. It is for output traceability. A public dataset should be logged and preserved. A clinical method should show validation. A policy study should show data and replication materials where lawful. A prototype should record tests and the chosen route. A negative result should be findable.

Patents appear here because WIPO provides a primary, comparable output series and because the contrast exposes the missing links. The same ledger that follows an invention to a filing should follow an open method to adoption. The policy error would be to treat all research as though one downstream count could measure it.

The deeper objection is administrative burden. Researchers already spend time on forms. A poorly designed ledger could add compliance without improving science. That is why reporting must reuse grant-management events, accept machine-readable outputs, and retire repetitive narrative forms. Traceability should reduce uncertainty, not create another ceremony.

Three moves to make the grant a beginning

1. Give every public research award a persistent project record. Owner: Ministry of Science and Technology. Success signal: the award, team, field, milestones, spending, outputs, data-access conditions, and final decisions are linked under one public identifier, with lawful redactions stated.
2. Fund independent validation and transition decisions. Owner: grant agencies with universities and problem-owning public bodies. Success signal: promising outputs receive documented replication, field testing, regulatory, open-release, patent, procurement, or stop decisions rather than disappearing after the final report.
3. Measure portfolios by routes to public value. Owner: national research councils and university regulators. Success signal: annual reporting distinguishes open datasets, replications, standards, domestic and foreign filings, licences, public adoption, firm adoption, and negative results without collapsing them into one score.

Bangladesh already has scientists and a mechanism for grants. The possibility lies in the space after selection. When every award leaves a trace through evidence, decision, and use, the state can learn which support works and researchers can build on one another. The pipeline ends at the grant only because the public record ends there. Extend the record, and the science can travel further.

---

Data note: WIPO patent data are system-level output signals. They cannot be causally attributed to Ministry grants from the available public sources. Applications and grants in the same year are not treated as a cohort conversion rate. Sources retrieved 2026-08-23.

Sources

1. Ministry of Science and Technology, Science and technology grant programme: https://most.gov.bd/pages/static-pages/694032c035ce18e1c0561b96
2. WIPO, Intellectual property statistical country profile: Bangladesh, 2024: https://www.wipo.int/edocs/statistics-country-profile/en/bd.pdf